Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma

A Corrigendum to this article was published on 08 December 2005

Abstract

Originally characterized as a growth factor for erythrocytes, erythropoietin (EPO) is used to treat anemia and fatigue in cancer patients receiving radiation therapy and chemotherapy. EPO and the EPO receptor (EPOR) are expressed in nonhematopoietic cells and cancers. However, the role of EPO and EPOR within nonhematopoietic cancer cells remains incompletely understood. Although a recent clinical trial demonstrated worse tumor control and survival in head and neck cancer patients treated with EPO, the role of EPO and EPOR in head and neck squamous cell carcinoma (HNSCC) has not been examined. In the present study, we demonstrate the previously unrecognized EPO-mediated invasion by HNSCC cells through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. Furthermore, we confirmed the expression of EPO and EPOR in a panel of human HNSCC cell lines and tissue specimens. Pharmacological doses of EPO also had a limited proliferation effect in these cell lines. These results define a novel role for EPO in mediating tumor cell invasion. Increased levels of EPO and EPOR in lymph node metastases as compared to primary tumors from HNSCC patients further support the role of EPO/EPOR in HNSCC disease progression and metastasis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K and Verma A . (2001). Cancer Res., 61, 3561–3565.

  • Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H and Verma A . (2003). Am. J. Pathol., 162, 1789–1806.

  • Acs G, Zhang PJ, Rebbeck TR, Acs P and Verma A . (2002). Cancer, 95, 969–981.

  • Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM and McEwan RN . (1987). Cancer Res., 47, 3239–3245.

  • Arcasoy M, Amin K, Chou SC, Haroon ZA, Varia M and Raleigh JA . (2005). Clin. Cancer Res., 11, 20–27.

  • Arcasoy M, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA and Haroon ZA . (2002). Lab. Invest., 82, 911–918.

  • BEST Investigators and Study Group (2003). Lancet Oncol., 4, 459–460.

  • Boucheron C, Dumon S, Santos SC, Moriggl R, Hennighausen L, Gisselbrecht S and Gouilleux F . (1998). J. Biol. Chem., 273, 33936–33941.

  • Chu YW, Runyan RB, Oshima RG and Hendrix MJ . (1993). Proc. Natl. Acad. Sci. USA, 90, 4261–4265.

  • David M, Wong L, Flavell R, Thompson SA, Wells A, Larner AC and Johnson GR . (1996). J. Biol. Chem., 271, 9185–9188.

  • Gall R and Kerr PD . (2000). J. Otolaryngol., 29, 131–134.

  • Glaser C, Millesi W, Kornek GV, Lang S, Schull B, Watzinger F, Selzer E and Lavey RS . (2001). Int. J. Radiat. Oncol. Biol. Phys., 50, 705–715.

  • Godfrey TE, Kim S-H, Chavira M, Ruff DW, Warren RS, Gray JW and Jensen RH . (2000). J. Mol. Diagn., 2, 84–91.

  • Grandis J, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ . (1998). J. Clin. Invest., 102, 1385–1392.

  • Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG and Morrow M (eds). 2002. AJCC Cancer Staging Manual, 6th edn. Springer-Verlag: New York.

  • Guo Y, Mascareno E and Siddiqui MA . (2004). Mol. Endocrinol., 18, 1033–1041.

  • Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C and Frommhold H . (2003). Lancet, 362, 1255–1260.

  • Heo D, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB and Whiteside TL . (1989). Cancer Res., 49, 5167–5175.

  • Hwa V, Little B, Kofoed EM and Rosenfeld RG . (2004). J. Biol. Chem., 279, 2728–2736.

  • Ihle J, Witthuhn BA, Quelle FW, Yamamoto K and Silvennoinen O . (1995). Annu. Rev. Immunol., 13, 369–398.

  • Jelkmann W . (1994). Clin. Invest., 72, S3–S10.

  • Jemal A, Thomas A, Murray T and Thom M . (2002). CA Cancer J. Clin., 52, 23–47.

  • Lacombe C and Mayeux P . (1999). Transplant, 14, 22–28.

  • Leong P, Xi S, Drenning SD, Dyer KF, Wentzel AL, Lerner EC, Smithgall TE and Grandis JR . (2002). Oncogene, 21, 2846–2853.

  • Littlewood T, Bajetta E, Nortier JW, Vercammen E, Rapoport B and Epoetin Alfa Study Group. (2001). J. Clin. Oncol., 19, 2865–2874.

  • Liu K, Gaffen SL and Goldsmith MA . (1998). Curr. Opin. Immunol., 10, 271–278.

  • Liu W, Powles T, Shamash J, Propper D, Oliver T and Joel S . (2004). Oncogene, 23, 981–990.

  • Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A and Hennighausen L . (1997). Genes Dev., 11, 179–186.

  • Meinke A, Barahmand-Pour F, Wohrl S, Stoiber D and Decker T . (1996). Mol. Cell. Biol., 16, 6937–6944.

  • Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A and Roifman CM . (1996). Nature, 379, 645–648.

  • Opdam F, Kamp M, de Bruijn R and Roos E . (2004). Oncogene, 23, 6647–6653.

  • Pajonk F, Weil A, Sommer A, Suwinski R and Henke M . (2004). Oncogene, 23, 8987–8991.

  • Sacks P, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S and Parsons DF . (1988). Cancer Res., 48, 2858–2866.

  • Shasha D . (2001). Semin. Hematol., 38, 8–15.

  • Tabbara I . (1993). Arch. Intern. Med., 153, 298–304.

  • Thatcher N . (1998). Semin. Oncol., 25, 23–26.

  • Thomas S, Copelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD and Grandis JR . (2003). Cancer Res., 63, 5629–5635.

  • Udy G, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ and Davey HW . (1997). Proc. Natl. Acad. Sci. USA, 94, 7239–7244.

  • Virolainen E, Carey TE, Wicha M and Krause CJ . (1983). Oto-HNS, 91, 126–135.

  • Wojchowski D, Gregory RC, Miller CP, Pandit AK and Pircher TJ . (1999). Exp. Cell Res., 253, 143–156.

  • Xi S, Zhang Q, Gooding WE, Smithgall TE and Grandis JR . (2003). Cancer Res., 63, 6763–6771.

  • Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, Onozaki M, Hashimoto M, Musha T, Ogawa K, Fujita H, Nakamura Y, Shiozaki H and Utsumi H . (2003). Carcinogenesis, 24, 1021–1029.

  • Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M and Sasaki R . (1998). J. Biol. Chem., 273, 25381–25387.

  • Yokomizo R, Matsuzaki S, Uehara S, Murakami T, Yaegashi N and Okamura K . (2002). Mol. Hum. Reprod., 8, 441–446.

  • Yoshimura A, Longmore G and Lodish HF . (1990). Nature, 348, 647–649.

  • Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, Leonard WJ and Broxmeyer HE . (2000). J Eukaryot Microbiol, 192, 719–728.

Download references

Acknowledgements

The authors thank Jonas T Johnson, Rebecca E Fraioli and Charles J Lin for critically reviewing this manuscript. This research was supported in part through the Young Clinical Scientist Award from the Flight Attendant Medical Research Institute (SYL), a National Institutes of Health T32 training grant (DC000066-01A2) and the Stout Family Fund for Head and Neck Cancer Research at the Eye & Ear Foundation of Pittsburgh.

Author information

Authors and Affiliations

Authors

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lai, S., Childs, E., Xi, S. et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24, 4442–4449 (2005). https://doi.org/10.1038/sj.onc.1208635

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208635

Keywords

This article is cited by

Search

Quick links